Investigating genetic and environmental factors in blood cancers.
InterLymph Consortium: interrogating pleiotropy and gene by environment interactions among hematopoietic malignancies.
This study is looking at how our genes and the environment might play a role in developing blood cancers like lymphomas and multiple myeloma, and it's for patients who want to help us understand these diseases better so we can improve how we predict who might be at risk.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | International Agency for Res on Cancer NIH-funded |
| Lab location | 1 site (Lyon, France) |
| Project ID | NIH-10898903 on NIH RePORTER |
What this research studies
This research focuses on understanding the genetic and environmental factors that contribute to blood cancers, specifically lymphomas and multiple myeloma. By conducting the largest genome-wide association study to date, the team aims to identify genetic variants linked to these diseases and how they interact with environmental exposures. Patients will be assessed for their genetic profiles and environmental factors to improve risk prediction for developing these cancers. The study will involve a large cohort of lymphoma patients and controls to ensure robust findings.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with lymphomas or multiple myeloma, particularly those aged 65 and older.
Not a fit: Patients with other types of cancers or those not diagnosed with lymphomas or multiple myeloma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved risk assessment and prevention strategies for blood cancers.
How similar studies have performed: Previous research has shown success in identifying genetic risk factors for blood cancers, making this approach promising for further advancements.
Where this research is happening
Lyon, France
- International Agency for Res on Cancer — Lyon, France (Active)
Researchers
- Principal investigator: Mckay, James Dowling — International Agency for Res on Cancer
- Study coordinator: Mckay, James Dowling
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.